Grouped Into 63 Collections of Similar Clauses From Business Contracts
This page contains Effective Date clauses in business contracts and legal agreements. We have organized these clauses into groups of similarly worded clauses.
Effective Date. Employee understands that this Agreement shall be null and void if not executed by him within twenty one (21) days. Employee has seven (7) days after that Party signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Employee signed this Agreement, so long as it has been signed by the Parties and has not been revoked by Employee before that date (the "Effective Date").
Effective Date. Employee Executive understands that this Agreement shall be null and void if not executed by him Executive within twenty one twenty-one (21) days. Employee Each Party has seven (7) days after that Party signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Employee Executive signed this Agreement, so long as it has been signed by the Parties and has not been revoked by Employee either Party before that date (the "Effective Date").
Effective Date. Employee understands that this Agreement shall be null and void if not executed by him her within twenty one twenty-one (21) days. days from the date this Agreement is presented. Employee has seven (7) days after that Party she signs this Agreement to revoke it. To be effective, any such revocation must be made in writing and delivered to John Foster on or before 5:00 p.m. PT on the seventh (7th) day. This Agreement will become effective on the eighth (8th) day after Employee signed this Agreeme...nt, so long as it has been signed by the Parties and has not been revoked by Employee before that date (the "Effective ("Effective Date"). View More
Effective Date. Employee Executive understands that this Agreement shall be null and void if not executed by him within twenty one (21) days. Employee days of the date this Agreement is presented to him by the Company. Executive has seven (7) days after that Party Executive signs this Agreement to revoke it. This Agreement will become effective on the eighth (8th) day after Employee Executive signed this Agreement, so long as it has been signed by the Parties and has not been revoked by Employee Executive befor...e that date (the "Effective Date"). View More
Effective Date. This Plan shall take effect on the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 12 APPENDIX A Designated Subsidiaries 13 EX-10.4 14 d120909dex10...4.htm EX-10.4 EX-10.4 Exhibit 10.4 CANDEL THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Candel Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the "Plan") is to provide eligible employees of Candel Therapeutics, Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.01 per share (the "Common Stock"). An aggregate of 293,000 shares of Common Stock have been approved and reserved for this purpose, plus on January 1, 2022, and each January 1 thereafter through January 1, 2031 the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 293,000 shares of Common Stock, (ii) one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in Section 1). The Plan includes two components: a Code Section 423 Component (the "423 Component") and a non-Code Section 423 Component (the "Non-423 Component"). It is intended for the 423 Component to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the "Code"), and the 423 Component shall be interpreted in accordance with that intent. Under the Non-423 Component, which does not qualify as an "employee stock purchase plan" within the meaning of Section 423(b) of the Code, options will be granted pursuant to rules, procedures or sub-plans adopted by the Administrator designed to achieve tax, securities laws or other objectives for eligible employees. Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in Section 11.View More
Effective Date. This Plan shall take effect on become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission Registration Date following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 12 APPENDIX A Designated... Subsidiaries 13 EX-10.4 14 d120909dex104.htm 6 d692551dex104.htm EX-10.4 EX-10.4 Exhibit 10.4 CANDEL THERAPEUTICS, PHREESIA, INC. 2021 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Candel Therapeutics, Phreesia, Inc. 2021 2019 Employee Stock Purchase Plan (the "Plan") ("the Plan") is to provide eligible employees of Candel Therapeutics, Phreesia, Inc. (the "Company") and each Designated Subsidiary Company (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.01 $0.001 per share (the "Common Stock"). An aggregate of 293,000 855,873 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2022, and each January 1 thereafter through January 1, 2031 the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 293,000 shares of Common Stock, (ii) one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in Section 1). purpose. The Plan includes two components: a Code Section 423 Component (the "423 Component") and a non-Code Section 423 Component (the "Non-423 Component"). It is intended for the 423 Component to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the "Code"), "Code") and the 423 Component shall be interpreted in accordance with that intent. Under the Non-423 Component, which does not qualify as an "employee stock purchase plan" within the meaning of Section 423(b) of the Code, options will be granted pursuant to rules, procedures or sub-plans adopted by the Administrator designed to achieve tax, securities laws or other objectives for eligible employees. Except as otherwise provided herein, herein or by the Administrator, the Non-423 Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this the Plan shall have the meaning ascribed to them in Section 11. View More
Effective Date. This Plan shall take effect on become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission Registration Date following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 12 APPENDIX A Designated... Subsidiaries 13 EX-10.4 14 d120909dex104.htm EX-10.4 EX-10.4 7 EX-10.2 10 d668054dex102.htm EX-10.2 EX-10.2 Exhibit 10.4 CANDEL THERAPEUTICS, 10.2 DYNATRACE, INC. 2021 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Candel Therapeutics, Dynatrace, Inc. 2021 2019 Employee Stock Purchase Plan (the "Plan") ("the Plan") is to provide eligible employees of Candel Therapeutics, Dynatrace, Inc. (the "Company") and each Designated Subsidiary Company (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.01 $0.001 per share (the "Common Stock"). An aggregate of 293,000 6,250,000 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January April 1, 2022, 2020, and each January April 1 thereafter through January April 1, 2031 2029, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 293,000 shares of Common Stock, (ii) one 1% percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December March 31st, (ii) 3,500,000 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in Section 1). The Plan includes two components: a Code Section 423 Component (the "423 Component") and a non-Code Section 423 Component (the "Non-423 Component"). It is intended for the 423 Component to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the "Code"), and the 423 Component shall be interpreted in accordance with that intent. Under the Non-423 Component, which does not qualify as an "employee stock purchase plan" within the meaning of Section 423(b) of the Code, options will be granted pursuant to rules, procedures or sub-plans adopted by the Administrator designed to achieve tax, securities comply with applicable laws or achieve tax and other objectives for eligible employees. objectives. Except as otherwise provided herein, herein or by the Administrator, the Non-423 Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in Section 11. View More
Effective Date. This Plan shall take effect on become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 12 11 APPENDIX A Designated Subsidiaries 1...3 EX-10.4 14 d120909dex104.htm EX-10.4 EX-10.4 12 EX-10.13 16 tm2032047d11_ex10-13.htm EXHIBIT 10.13 Exhibit 10.4 CANDEL THERAPEUTICS, 10.13 908 DEVICES INC. 2021 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Candel Therapeutics, 908 Devices Inc. 2021 2020 Employee Stock Purchase Plan (the "Plan") is to provide eligible employees of Candel Therapeutics, 908 Devices Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.01 $0.001 per share (the "Common Stock"). An aggregate of 293,000 288,857 shares of Common Stock have been approved and reserved for this purpose, plus on January 1, 2022, and each January 1 thereafter through January 1, 2031 2030, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 293,000 307,295 shares of Common Stock, (ii) one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in Section 1). The Plan includes two components: a Code Section 423 Component (the "423 Component") and a non-Code Section 423 Component (the "Non-423 Component"). It is intended for the 423 Component to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the "Code"), and the 423 Component shall be interpreted in accordance with that intent. Under the Non-423 Component, which does not qualify as an "employee stock purchase plan" within the meaning of Section 423(b) of the Code, options will be granted pursuant to rules, procedures or sub-plans adopted by the Administrator designed to achieve tax, securities laws or other objectives for eligible employees. Except as otherwise provided herein, the Non-423 Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in Section 11. View More
Effective Date. The MHC Merger shall not be effective until and unless the Plan is approved by the Board of Governors of the Federal Reserve System (the "Federal Reserve") after approval of this MHC Merger Agreement by at least (i) two-thirds of the votes eligible to be cast by the Stockholders of the Mid-Tier Holding Company, (ii) a majority of the votes eligible to be cast by Minority Stockholders, and (iii) a majority of the votes eligible to be cast by Voting Members, and the Articles of Combination shall h...ave been filed with the Federal Reserve with respect to the MHC Merger. Approval of the Plan by the Voting Members shall constitute approval of the MHC Merger Agreement by the Voting Members. Approval of the Plan by Minority Stockholders of the Mid-Tier Holding Company, including the Minority Stockholders, shall constitute approval of the MHC Merger Agreement by such stockholders.View More
Effective Date. The MHC Merger shall not be effective until and unless the Plan is approved by the Board of Governors of the Federal Reserve System (the "Federal Reserve") after approval of this MHC Merger Agreement by at least least: (i) two-thirds of the total votes eligible to be cast by the Stockholders of the Mid-Tier Holding Company, Stockholders; (ii) a majority of the total votes eligible to be cast by Minority Stockholders, Stockholders; and (iii) a majority of the votes eligible to be cast by Voting M...embers, and the Articles of Combination shall have been filed with the Federal Reserve with respect to the MHC Merger. Approval of the Plan by the Voting Members shall constitute approval of the this MHC Merger Agreement by the Voting Members. Approval of the Plan by Minority Stockholders of the Mid-Tier Holding Company, Stockholders, including the Minority Stockholders, shall constitute approval of the this MHC Merger Agreement by such stockholders. the Stockholders. View More
Effective Date. The MHC Merger shall not be effective until and unless the Plan is approved by the Board of Governors of the Federal Reserve System (the "Federal Reserve") after approval of this MHC Merger Agreement by by: (i) at least (i) two-thirds of the total votes eligible to be cast by the Stockholders of the Mid-Tier Holding Company, Stockholders; (ii) a majority of the total votes eligible to be cast by Minority Stockholders, Stockholders; and (iii) a majority of the votes eligible to be cast by Voting ...Members, and the Articles of Combination shall have been filed with the Federal Reserve with respect to the MHC Merger. Approval of the Plan by the Voting Members shall constitute approval of the this MHC Merger Agreement by the Voting Members. Approval of the Plan by Minority Stockholders of the Mid-Tier Holding Company, Stockholders, including the Minority Stockholders, shall constitute approval of the this MHC Merger Agreement by such stockholders. the Stockholders. View More
Effective Date. The MHC Merger shall not be effective until and unless the Plan is approved by the Board of Governors of the Federal Reserve System (the "Federal Reserve") and the Department after approval of this MHC Merger Agreement by (i) at least (i) two-thirds of the votes eligible to be cast by the Stockholders of the Mid-Tier Holding Company, (ii) a majority of the votes eligible to be cast by Minority Stockholders, and (iii) a majority of the votes eligible to be cast by Voting Members, Depositors, and ...the Articles Certificate of Combination Merger shall have been filed with the Federal Reserve applicable state authorities with respect to the MHC Merger. Approval of the Plan by the Voting Members Depositors shall constitute approval of the MHC Merger Agreement by the Voting Members. Depositors. Approval of the Plan by Minority Stockholders of the Mid-Tier Holding Company, including the Minority Stockholders, shall constitute approval of the MHC Merger Agreement by such stockholders. Stockholders. View More
Effective Date. This Plan shall become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 10 APPENDIX A Designated Subsidiaries None 11 EX-10.3 8 t...v527886_ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 SPRINGWORKS THERAPEUTICS, INC. 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the SpringWorks Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("the Plan") is to provide eligible employees of SpringWorks Therapeutics, Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). An aggregate of 442,153 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2020, and each January 1 thereafter through January 1, 2029, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) one percent (1%) percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, (ii) 663,229 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator. The Plan is intended to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the "Code"), and shall be interpreted in accordance with that intent.View More
Effective Date. This Plan shall become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 10 APPENDIX A Designated Subsidiaries None None. 11 EX-10....3 8 tv527886_ex10-3.htm 13 a2238646zex-10_3.htm EX-10.3 EXHIBIT 10.3 Exhibit 10.3 SPRINGWORKS THERAPEUTICS, AXCELLA HEALTH INC. 2019 EMPLOYEE STOCK PURCHASE PLAN The purpose of the SpringWorks Therapeutics, Axcella Health Inc. 2019 Employee Stock Purchase Plan ("the Plan") is to provide eligible employees of SpringWorks Therapeutics, Axcella Health Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.0001 $0.001 per share (the "Common Stock"). An aggregate of 442,153 237,181 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2020, and each January 1 thereafter through January 1, 2029, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) one percent (1%) percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, (ii) 663,229 237,181 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator. The Plan is intended to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the "Code"), and shall be interpreted in accordance with that intent. View More
Effective Date. This Plan shall become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. DATE APPROVED BY BOARD OF DIRECTORS: AUGUST 11, 2020 DATE... APPROVED BY STOCKHOLDERS: AUGUST 14, 2020 10 APPENDIX A Designated Subsidiaries None None. 11 EX-10.3 8 tv527886_ex10-3.htm EXHIBIT 10.3 EX-10.5 9 d940105dex105.htm EX-10.5 EX-10.5 Exhibit 10.3 SPRINGWORKS 10.5 KYMERA THERAPEUTICS, INC. 2019 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the SpringWorks Kymera Therapeutics, Inc. 2019 2020 Employee Stock Purchase Plan ("the Plan") (the "Plan") is to provide eligible employees of SpringWorks Kymera Therapeutics, Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). An aggregate of 442,153 445,653 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2020, 2021, and each January 1 thereafter through January 1, 2029, 2030, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) one percent (1%) percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, (ii) 663,229 438,898 shares of Common Stock Stock, or (iii) such number of shares of Common Stock as determined by the Administrator. The Plan is intended to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the "Code"), and shall be interpreted in accordance with that intent. View More
Effective Date. This Plan shall become effective upon the date immediately preceding the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the Securities and Exchange Commission following stockholder approval in accordance with applicable state law, the Company's bylaws and articles of incorporation, each as amended, and applicable stock exchange rules. 10 APPENDIX A Designated Subsidiaries None 11 EX-10.3 8 t...v527886_ex10-3.htm EXHIBIT 10.3 EX-10.11 13 d945651dex1011.htm EX-10.11 EX-10.11 Exhibit 10.3 SPRINGWORKS THERAPEUTICS, 10.11 PRAXIS PRECISION MEDICINES, INC. 2019 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the SpringWorks Therapeutics, Praxis Precision Medicines, Inc. 2019 2020 Employee Stock Purchase Plan ("the Plan") (the "Plan") is to provide eligible employees of SpringWorks Therapeutics, Praxis Precision Medicines, Inc. (the "Company") and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). An aggregate of 442,153 327,102 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2020, 2021, and each January 1 thereafter through January 1, 2029, 2030, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) one percent (1%) percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, (ii) 663,229 327,102 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator. The Plan is intended to constitute an "employee stock purchase plan" within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the "Code"), and shall be interpreted in accordance with that intent. View More
Effective Date. Employee understands that this Agreement shall be null and void if not executed by Employee and received by the Company on or before October 1, 2021. This Agreement will become effective on the date it has been signed by both Parties (the "Effective Date").
Effective Date. Employee understands that this Agreement shall be null and void if not executed by Employee and received by the Company on or before October 1, 2021. within seven (7) days. This Agreement will become effective on the date it has been signed by both Parties (the "Effective Date").
Effective Date. Employee understands that this Agreement shall be null and void if not executed by Employee and received by the Company on or before October 1, November 12, 2021. This Agreement will become effective on the date it has been signed by both Parties (the "Effective Date").
Effective Date. This Appendix A was initially adopted by the Board on April 7, 2014 and by the stockholders of the Company on June 7, 2014. The Board approved the Second Amended and Restated Stock Plan, including Appendix A, on April 15, 2019 (the "Effective Date"), and the stockholders of the Company subsequently approved the same on May 31, 2019. This Appendix A shall continue in effect for a term of ten (10) years from the Effective Date, unless sooner terminated in accordance with Section 16 of the Plan.
Effective Date. This Appendix A was initially adopted by the Board on April 7, 2014 and by the stockholders of the Company on June 7, 2014. The Board approved the Second Amended and Restated Stock Plan, including Appendix A, on April 15, 2019 (the "Effective Date"), Date") and the stockholders of the Company subsequently approved the same on May 31, 2019. This Appendix A it shall continue in effect for a term of ten (10) years from the Effective Date, unless sooner terminated in accordance with Section 16 subje...ct to the approval of the Plan. stockholders of the Corporation. View More
Effective Date. For purposes of this Agreement, the "Effective Date" shall mean the date when this Agreement becomes fully executed by all parties hereto.
Effective Date. For purposes of this Agreement, the "Effective Date" Pate" shall mean the date when this this. Agreement becomes ‘becomes fully executed by all parties hereto.
Effective Date. For purposes of this Agreement, the "Effective Date" shall mean the date when this Agreement becomes fully executed by all parties hereto.
Effective Date. This Plan is adopted, and is to be effective, as of the first day of Progressive's 2017 fiscal year. This Plan shall be effective for the 2017 Plan year and for each Plan year thereafter unless and until terminated by the Committee.
Effective Date. This Plan is adopted, and is to be effective, as of the first day of Progressive's 2017 2020 fiscal year. This Plan shall be effective for the 2017 2020 Plan year and for each Plan year thereafter unless and until terminated by the Committee.
Effective Date. Except as otherwise provided herein, this Agreement shall be deemed effective as of such date as the Company and the Holder shall have duly executed and delivered this Agreement (the "Effective Date"). 6 11. No Commissions. Neither the Company nor the Holder has paid or given, or will pay or give, to any person, any commission, fee or other remuneration, directly or indirectly, in connection with the transactions contemplated by this Agreement.
Effective Date. Except as otherwise provided herein, this Agreement shall be deemed effective as of such date as the Company and the Holder Investor shall have duly executed and delivered this Agreement (the "Effective Date"). 4 6. 11. No Commissions. Neither the Company nor the Holder Investor has paid or given, or will pay or give, to any person, any commission, fee or other remuneration, directly or indirectly, in connection with the transactions contemplated by this Agreement.
Effective Date. Except as otherwise provided herein, this Agreement shall be deemed effective as of such date as that both (a) the Company and the Holder shall have duly executed and delivered this Agreement and (b) the Company has paid the Legal Fee Amount (the "Effective Date"). 6 11 11. No Commissions. Neither the Company nor the Holder has paid or given, or will pay or give, to any person, any commission, fee or other remuneration, directly or indirectly, in connection with the transactions contemplated by ...this Agreement. View More